Blog

class actions

The U.S. Supreme Court has decline to hear argument over “objective falsehood” under the False Claims Act (FCA). This has been a hot button issue in litigation that has federal courts split and
555f45230745810d755a31fdc6dbd9c835d600b7_large

Two members of the Sackler family testified in front of Congress this month. David and Kathe Sackler both held executive positions and were active members on Purdue Pharma’s board during the time when
DOJ Emblem

As U.S. prosecutors go through document in an attempt to hold drug companies, distributors, and pharmacies accountable to the part they played in the U.S. opioid epidemic, emails uncover another bad faith actor. Purdue
Screen Shot 2020-02-24 at 5.45.16 PM

As the COVID-19 pandemic continues to plague America, worsening the opioid crisis that has plagued the nation for decades, litigation to recoup the cost of fighting the opioid crisis has stalled. While local

The opioid crisis has highlighted problems with Pennsylvania’s prescription drug monitoring system. Over the past few years the Pennsylvania Department of Health has worked on a statewide database for monitoring schedule II –
risperdal, boy,sad,breasts,sheller,lawsuit,lawyer,verdict

A Pennsylvania Superior Court has rejected Johnson & Johnson’s appeal of a 2016 $70 million verdict awarded to a 20 year-old Tennessee man, Andrew Yount (A.Y.) who developed gynecomastia after taking the antipsychotic
Risperdal green tablet

In a 6 to 1 decision, the Pennsylvania Supreme Court opened the door for thousands of pending Risperdal injury cases to proceed to trial. The seven-justice court ruled that a jury must decide,
Risperdal green tablet

October 9, 2019: Late yesterday a Philadelphia jury rendered an $8 billion punitive damages verdict against pharmaceutical company Johnson & Johnson for illegally marketing the antipsychotic drug Risperdal, putting young boys at risk for developing female-sized breast
Screen-Shot-2019-01-25-at-3.34.17-PM

An Oklahoma judge order Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals to pay a $572 million fine to the state for fueling the opioid crisis. This was the first case of its kind
pharma

Philadelphia District Attorney Larry Krasner has been given approval by a state judge to move forward with with action against drugmakers and distributors for illegal marketing and sales of opioid painkillers resulting in a nationwide